Top

Published in:

02-02-2023 | Metastasis | Invited Review

Circulating biomarkers for diagnosis and therapeutic monitoring in bone metastasis

Authors: Min-Kyoung Song, Serk In Park, Sun Wook Cho

Published in: Journal of Bone and Mineral Metabolism | Issue 3/2023

Abstract

Bone is a frequent site of metastasis for multiple types of solid tumors in organs such as prostate, breast, lung, etc., accounting for significant morbidities and mortalities of afflicted patients. One of the major problems of bone metastasis is lack of biomarkers for early diagnosis and for monitoring therapeutic responses. Medical imaging modalities such as computerized tomography, magnetic resonance imaging, and radioactive isotope-based bone scans are currently standard clinical practices, yet these imaging techniques are limited to detect early lesions or to accurately monitor the metastatic disease progression during standard and/or experimental therapies. Accordingly, development of novel blood biomarkers rationalizes extensive basic research and clinical development. This review article covers the up-to-date information on protein- and cell-based biomarkers of bone metastasis that are currently used in the clinical practices and also are under development.

Available only for authorised users

Hofbauer LC, Rachner TD, Coleman RE, Jakob F (2014) Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol 2:500–512. https://doi.org/10.1016/S2213-8587(13)70203-1CrossRefPubMed

Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593. https://doi.org/10.1038/nrc867CrossRefPubMed

Eriksen EF, Axelrod DW, Melsen F (1994) Bone histomorphometry. Raven Press

Shiozawa Y, Pedersen EA, Havens AM et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121:1298–1312. https://doi.org/10.1172/JCI43414CrossRefPubMedPubMedCentral

Shiozawa Y, Pienta KJ, Taichman RS (2011) Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 17:5553–5558. https://doi.org/10.1158/1078-0432.CCR-10-2505CrossRefPubMedPubMedCentral

Jeong HM, Cho SW, Park SI (2016) Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment. Endocrinol Metab 31:485–492. https://doi.org/10.3803/EnM.2016.31.4.485CrossRef

Cook GJR, Azad GK, Goh V (2016) Imaging bone metastases in breast cancer: staging and response assessment. J Nucl Med 57:27S-33S. https://doi.org/10.2967/jnumed.115.157867CrossRefPubMed

Goyal N, Kalra M, Soni A et al (2019) Multi-modality imaging approach to bone tumors - State-of-the art. J Clin Orthop Trauma 10:687–701. https://doi.org/10.1016/j.jcot.2019.05.022CrossRefPubMedPubMedCentral

Koizumi M, Matsumoto S, Takahashi S et al (1999) Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med 24:15–20. https://doi.org/10.1097/00003072-199901000-00004CrossRefPubMed

10.

Hirahata T, Ul Quraish R, Quraish AU et al (2022) Liquid biopsy: a distinctive approach to the diagnosis and prognosis of cancer. Cancer Inform 21:11769351221076062. https://doi.org/10.1177/11769351221076062CrossRefPubMedPubMedCentral

11.

Coleman R, Costa L, Saad F et al (2011) Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol 80:411–432. https://doi.org/10.1016/j.critrevonc.2011.02.005CrossRefPubMed

12.

Coleman RE, Lipton A, Costa L et al (2013) Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. J bone Oncol 2:70–76. https://doi.org/10.1016/j.jbo.2013.01.002CrossRefPubMedPubMedCentral

13.

Tamiya M, Tokunaga S, Okada H et al (2013) Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer. Clin Lung Cancer 14:364–369. https://doi.org/10.1016/j.cllc.2012.11.006CrossRefPubMed

14.

Coleman RE, Major P, Lipton A et al (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925–4935. https://doi.org/10.1200/JCO.2005.06.091CrossRefPubMed

15.

Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69. https://doi.org/10.1093/jnci/dji002CrossRefPubMed

16.

Lara PNJ, Ely B, Quinn DI et al (2014) Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst 106:dju013. https://doi.org/10.1093/jnci/dju013CrossRefPubMedPubMedCentral

17.

Jung K, Lein M, Stephan C et al (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J cancer 111:783–791. https://doi.org/10.1002/ijc.20314CrossRefPubMed

18.

Brown J, Rathbone E, Hinsley S et al (2018) Associations between serum bone biomarkers in early breast cancer and development of bone metastasis: results from the AZURE (BIG01/04) trial. J Natl Cancer Inst 110:871–879. https://doi.org/10.1093/jnci/djx280CrossRefPubMedPubMedCentral

19.

Lipton A, Chapman J-AW, Demers L et al (2011) Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol 29:3605–3610. https://doi.org/10.1200/JCO.2010.31.5069CrossRefPubMed

20.

Kong QQ, Sun TW, Dou QY et al (2007) Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer. Int J Biol Markers 22:214–220. https://doi.org/10.5301/jbm.2008.3777CrossRefPubMed

21.

Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E (2007) Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178:849–853. https://doi.org/10.1016/j.juro.2007.05.029CrossRefPubMed

22.

Wada N, Fujisaki M, Ishii S et al (2001) Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer 8:131–137. https://doi.org/10.1007/BF02967492CrossRefPubMed

23.

Lumachi F, Basso SMM, Camozzi V et al (2016) Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy. Clin Chim acta 460:227–230. https://doi.org/10.1016/j.cca.2016.07.005CrossRefPubMed

24.

Lyubimova NV, Pashkov MV, Tyulyandin SA et al (2004) Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull Exp Biol Med 138:77–79. https://doi.org/10.1023/b:bebm.0000046945.95479.d6CrossRefPubMed

25.

Salminen E, Ala-Houhala M, Korpela J et al (2005) Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer. Acta Oncol (Madr) 44:742–747. https://doi.org/10.1080/02841860500327586CrossRef

26.

Elfar GA, Ebrahim MA, Elsherbiny NM, Eissa LA (2017) Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer. Oncol Res 25:641–650. https://doi.org/10.3727/096504016X14768398678750CrossRefPubMedPubMedCentral

27.

Oremek G, Sauer-Eppel H, Klepzig M (2007) Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas. Anticancer Res 27:1961–1962PubMed

28.

Westerhuis LW, Delaere KP (1997) Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer. Eur J Clin Chem Clin Biochem 35:89–94. https://doi.org/10.1515/cclm.1997.35.2.89CrossRefPubMed

29.

Brown JE, Cook RJ, Lipton A et al (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 123:767–779. https://doi.org/10.1007/s10549-010-0981-1CrossRefPubMed

30.

Du W-X, Duan S-F, Chen J-J et al (2014) Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review and meta-analysis. J Cancer Res Ther 10:C140–C143. https://doi.org/10.4103/0973-1482.145842CrossRefPubMed

31.

Lipton A, Smith MR, Fizazi K et al (2016) Changes in bone turnover marker levels and clinical outcomes in patients with advanced cancer and bone metastases treated with bone antiresorptive agents. Clin cancer Res 22:5713–5721. https://doi.org/10.1158/1078-0432.CCR-15-3086CrossRefPubMed

32.

Zhao H, Han K-L, Wang Z-Y et al (2011) Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors. Med Sci Monit 17:CR626-633. https://doi.org/10.12659/msm.882047CrossRefPubMedPubMedCentral

33.

Arai Y, Takeuchi H, Oishi K, Yoshida O (1992) Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate 20:169–177. https://doi.org/10.1002/pros.2990200302CrossRefPubMed

34.

Terpos E, Kiagia M, Karapanagiotou EM et al (2009) The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 29:1651–1657PubMed

35.

Bayrak SB, Ceylan E, Serter M et al (2012) The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer. Int J Clin Oncol 17:112–118. https://doi.org/10.1007/s10147-011-0266-7CrossRefPubMed

36.

Lee K-H, Lee KJ, Kim T-Y et al (2020) Circulating Osteocalcin-positive cells as a novel diagnostic biomarker for bone metastasis in breast cancer patients. J Bone Miner Res 35:1838–1849. https://doi.org/10.1002/jbmr.4041CrossRefPubMed

37.

Larson SR, Zhang X, Dumpit R et al (2013) Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate 73:932–940. https://doi.org/10.1002/pros.22639CrossRefPubMedPubMedCentral

38.

Hesse E, Schröder S, Brandt D et al (2019) Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. https://doi.org/10.1172/jci.insight.125543CrossRefPubMedPubMedCentral

39.

Rachner TD, Göbel A, Thiele S et al (2014) Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast cancer Res 16:R20. https://doi.org/10.1186/bcr3616CrossRefPubMedPubMedCentral

40.

Kasoha M, Bohle RM, Seibold A et al (2018) Dickkopf-1 (Dkk1) protein expression in breast cancer with special reference to bone metastases. Clin Exp Metastasis 35:763–775. https://doi.org/10.1007/s10585-018-9937-3CrossRefPubMed

41.

Qiao R, Zhong R, Chang Q et al (2017) Serum dickkopf-1 as a clinical and prognostic factor in non-small cell lung cancer patients with bone metastases. Oncotarget 8:79469–79479. https://doi.org/10.18632/oncotarget.18446CrossRefPubMedPubMedCentral

42.

Ramankulov A, Lein M, Kristiansen G et al (2007) Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 133:643–652. https://doi.org/10.1007/s00432-007-0215-zCrossRefPubMed

43.

Ramankulov A, Lein M, Kristiansen G et al (2007) Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67:330–340. https://doi.org/10.1002/pros.20540CrossRefPubMed

44.

Hiraki A, Ueoka H, Bessho A et al (2002) Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. Cancer 95:1706–1713. https://doi.org/10.1002/cncr.10828CrossRefPubMed

45.

Washam CL, Byrum SD, Leitzel K et al (2013) Identification of PTHrP(12–48) as a plasma biomarker associated with breast cancer bone metastasis. Cancer Epidemiol Biomark Prev 22:972–983. https://doi.org/10.1158/1055-9965.EPI-12-1318-TCrossRef

46.

Abuzallouf S, Dayes I, Lukka H (2004) Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 171:2122–2127. https://doi.org/10.1097/01.ju.0000123981.03084.06CrossRefPubMed

47.

Briganti A, Suardi N, Gallina A et al (2014) Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev 40:3–11. https://doi.org/10.1016/j.ctrv.2013.07.001CrossRefPubMed

48.

Sutherland A, Forsyth A, Cong Y et al (2016) The role of prolactin in bone metastasis and breast cancer cell-mediated osteoclast differentiation. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv338CrossRefPubMed

49.

D’Amico L, Belisario D, Migliardi G et al (2016) C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. Oncotarget 7:45525–45537. https://doi.org/10.18632/oncotarget.9997CrossRefPubMedPubMedCentral

50.

Lee SK, Park K-K, Kim H-J et al (2017) Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis. Sci Rep 7:9610. https://doi.org/10.1038/s41598-017-09040-4CrossRefPubMedPubMedCentral

51.

Wang J, You H, Qi J et al (2017) Autocrine and paracrine STIP1 signaling promote osteolytic bone metastasis in renal cell carcinoma. Oncotarget 8:17012–17026. https://doi.org/10.18632/oncotarget.15222CrossRefPubMedPubMedCentral

52.

Tiedemann K, Sadvakassova G, Mikolajewicz N et al (2019) Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl Oncol 12:462–474. https://doi.org/10.1016/j.tranon.2018.11.014CrossRefPubMed

53.

Helo P, Cronin AM, Danila DC et al (2009) Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with Cell Search assay and association with bone metastases and with survival. Clin Chem 55:765–773. https://doi.org/10.1373/clinchem.2008.117952CrossRefPubMedPubMedCentral

54.

De Giorgi U, Valero V, Rohren E et al (2010) Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 21:33–39. https://doi.org/10.1093/annonc/mdp262CrossRefPubMed

55.

Cheng M, Liu L, Yang H-S, Liu G-F (2014) Circulating tumor cells are associated with bone metastasis of lung cancer. Asian Pacif J cancer Prev 15:6369–6374. https://doi.org/10.7314/apjcp.2014.15.15.6369CrossRef

56.

Pantano F, Rossi E, Iuliani M et al (2020) Dynamic changes of receptor activator of nuclear factor-κB expression in circulating tumor cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. Sci Rep 10:1288. https://doi.org/10.1038/s41598-020-58339-2CrossRefPubMedPubMedCentral

57.

Rizzo FM, Vesely C, Childs A et al (2019) Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. Br J Cancer 120:294–300. https://doi.org/10.1038/s41416-018-0367-4CrossRefPubMedPubMedCentral

58.

Zhu L, Loo WTY, Chow LWC (2005) Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes. Biomed Pharmacother 59:S355–S358. https://doi.org/10.1016/s0753-3322(05)80077-0CrossRefPubMed

59.

Zhu L, Loo WTY, Cheng CWN, Chow LWC (2006) Possible predictive markers related to micro-metastasis in breast cancer patients. Oncol Rep 15:1217–1223PubMed

60.

Trapp EK, Fasching PA, Fehm T et al (2022) Does the presence of circulating tumor cells in high-risk early breast cancer patients predict the site of first metastasis-results from the adjuvant SUCCESS a trial. Cancers (Basel). https://doi.org/10.3390/cancers14163949CrossRefPubMed

61.

Iuliani M, Simonetti S, Ribelli G et al (2020) Current and emerging biomarkers predicting bone metastasis development. Front Oncol 10:789. https://doi.org/10.3389/fonc.2020.00789CrossRefPubMedPubMedCentral

62.

Plaks V, Koopman CD, Werb Z (2013) Cancer circulating tumor cells. Science 341:1186–1188. https://doi.org/10.1126/science.1235226CrossRefPubMed

63.

Tian R, Li X, Zhang H et al (2022) Ulex Europaeus agglutinin-I-based magnetic isolation for the efficient and specific capture of SW480 circulating colorectal tumor cells. ACS Omega 7:30405–30411. https://doi.org/10.1021/acsomega.2c03702CrossRefPubMedPubMedCentral

64.

Kolostova K, Spicka J, Matkowski R, Bobek V (2015) Isolation, primary culture, morphological and molecular characterization of circulating tumor cells in gynecological cancers. Am J Transl Res 7:1203–1213PubMedPubMedCentral

65.

Yoon J, Yoon H-S, Shin Y et al (2017) Ethanol-dispersed and antibody-conjugated polymer nanofibers for the selective capture and 3-dimensional culture of EpCAM-positive cells. Nanomedicine 13:1617–1625. https://doi.org/10.1016/j.nano.2017.02.015CrossRefPubMed

66.

Eghbali-Fatourechi GZ, Lamsam J, Fraser D et al (2005) Circulating osteoblast-lineage cells in humans. N Engl J Med 352:1959–1966. https://doi.org/10.1056/NEJMoa044264CrossRefPubMed

67.

Dumez B, Van Damme K, Casteleyn L (2007) Research on the socio-ethical impact of biomarker use and the communication processes in ECNIS NoE and NewGeneris IP. Int J Hyg Environ Health 210:263–265. https://doi.org/10.1016/j.ijheh.2007.01.018CrossRefPubMed

68.

Suda RK, Billings PC, Egan KP et al (2009) Circulating osteogenic precursor cells in heterotopic bone formation. Stem Cells 27:2209–2219. https://doi.org/10.1002/stem.150CrossRefPubMed

69.

De Potter P, von Weymarn C, Zografos L (1991) In vivo phosphorus 31 magnetic resonance spectroscopy of human uveal melanomas and other intraocular tumors. Am J Ophthalmol 111:276–288. https://doi.org/10.1016/s0002-9394(14)72310-4CrossRefPubMed

70.

Undale A, Srinivasan B, Drake M et al (2010) Circulating osteogenic cells: characterization and relationship to rates of bone loss in postmenopausal women. Bone 47:83–92. https://doi.org/10.1016/j.bone.2010.03.018CrossRefPubMedPubMedCentral

71.

Rubin MR, Manavalan JS, Dempster DW et al (2011) Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism. J Clin Endocrinol Metab 96:176–186. https://doi.org/10.1210/jc.2009-2682CrossRefPubMed

72.

Egan KP, Duque G, Keenan MA, Pignolo RJ (2018) Circulating osteogentic precursor cells in non-hereditary heterotopic ossification. Bone 109:61–64. https://doi.org/10.1016/j.bone.2017.12.028CrossRefPubMed

73.

Johnson RW (2020) The search for a bone metastasis biomarker may have a new find: circulating osteocalcin-positive cells. J Bone Miner Res 35:1836–1837CrossRefPubMed

74.

Lee C, Whang YM, Campbell P et al (2018) Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis. Cancer Lett 414:205–213. https://doi.org/10.1016/j.canlet.2017.11.016CrossRefPubMed

75.

Park SI, Lee C, Sadler WD et al (2013) Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res 73:6574–6583. https://doi.org/10.1158/0008-5472.CAN-12-4692CrossRefPubMed

76.

Zheng Y, Chow S-O, Boernert K et al (2014) Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways. J Bone Miner Res 29:1938–1949. https://doi.org/10.1002/jbmr.2231CrossRefPubMed

77.

Swami S, Johnson J, Bettinson LA et al (2017) Prevention of breast cancer skeletal metastases with parathyroid hormone. JCI Insight. https://doi.org/10.1172/jci.insight.90874CrossRefPubMedPubMedCentral

78.

Devignes C-S, Aslan Y, Brenot A et al (2018) HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice. Proc Natl Acad Sci USA 115:E992–E1001. https://doi.org/10.1073/pnas.1718009115CrossRefPubMedPubMedCentral

79.

Masucci MT, Minopoli M, Carriero MV (2019) Tumor associated neutrophils their role in tumorigenesis, metastasis Prognosis and Therapy. Front Oncol 9:1146. https://doi.org/10.3389/fonc.2019.01146CrossRefPubMedPubMedCentral

80.

Thio QCBS, Goudriaan WA, Janssen SJ et al (2018) Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases. Br J Cancer 119:737–743. https://doi.org/10.1038/s41416-018-0231-6CrossRefPubMedPubMedCentral

81.

Wang S, Zhang Z, Fang F et al (2011) The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett 2:735–740. https://doi.org/10.3892/ol.2011.304CrossRefPubMedPubMedCentral

82.

Caliskan B, Korkmaz AN (2016) Can Neutrophil/Lymphocyte Ratio be a Predictor for Bone Metastases of Solid Tumors? World J Nucl Med 15:196–199. https://doi.org/10.4103/1450-1147.174711CrossRefPubMedPubMedCentral

83.

Camerer E, Qazi AA, Duong DN et al (2004) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104:397–401. https://doi.org/10.1182/blood-2004-02-0434CrossRefPubMed

84.

Felding-Habermann B, Fransvea E, O’Toole TE et al (2002) Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis 19:427–436. https://doi.org/10.1023/a:1016377114119CrossRefPubMed

85.

Bakewell SJ, Nestor P, Prasad S et al (2003) Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 100:14205–14210. https://doi.org/10.1073/pnas.2234372100CrossRefPubMedPubMedCentral

86.

Boucharaba A, Serre C-M, Grès S et al (2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 114:1714–1725. https://doi.org/10.1172/JCI22123CrossRefPubMedPubMedCentral

87.

Park SI, Liao J, Berry JE et al (2012) Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res 72:2522–2532. https://doi.org/10.1158/0008-5472.CAN-11-2928CrossRefPubMedPubMedCentral

88.

Lee EJ, Jung S, Park KH, Park SI (2022) Flow cytometry-based immunophenotyping of myeloid-derived suppressor cells in human breast cancer patient blood samples. J Immunol Methods 510:113348. https://doi.org/10.1016/jj.im.2022.113348CrossRefPubMed

Title: Circulating biomarkers for diagnosis and therapeutic monitoring in bone metastasis
Authors: Min-Kyoung Song
Serk In Park
Sun Wook Cho
Publication date: 02-02-2023
Publisher: Springer Nature Singapore
Keywords: Metastasis
Breast Cancer
Breast Cancer
Bone Metastasis
Biomarkers
Published in: Journal of Bone and Mineral Metabolism / Issue 3/2023
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-022-01396-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2023

Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer

Wnt signaling: a double-edged sword in protecting bone from cancer

Extracellular vesicles in bone homeostasis: key roles of physiological and pathological conditions

Immunotherapy as a potential treatment approach for currently incurable bone metastasis

Management of cancer pain due to bone metastasis

Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials